On Friday, Halozyme Therapeutics Inc (NASDAQ: HALO) was -1.63% drop from the session before settling in for the closing price of $71.19. A 52-week range for HALO has been $42.01 – $79.50.
When this article was written, the company’s average yearly earnings per share was at 48.32%. With a float of $116.24 million, this company’s outstanding shares have now reached $117.52 million.
Halozyme Therapeutics Inc (HALO) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Halozyme Therapeutics Inc stocks. The insider ownership of Halozyme Therapeutics Inc is 1.16%, while institutional ownership is 102.98%. The most recent insider transaction that took place on Nov 12 ’25, was worth 1,410,990. In this transaction PRESIDENT AND CEO of this company sold 20,000 shares at a rate of $70.55, taking the stock ownership to the 733,719 shares. Before that another transaction happened on Nov 11 ’25, when Company’s PRESIDENT AND CEO sold 20,000 for $69.13, making the entire transaction worth $1,382,600. This insider now owns 733,719 shares in total.
Halozyme Therapeutics Inc (HALO) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted 1.26 earnings per share (EPS) during the time that was better than consensus figure (set at 1.16) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.74 per share during the current fiscal year.
Halozyme Therapeutics Inc (NASDAQ: HALO) Trading Performance Indicators
You can see what Halozyme Therapeutics Inc (HALO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.63. Likewise, its price to free cash flow for the trailing twelve months is 13.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 4.76, a number that is poised to hit 1.92 in the next quarter and is forecasted to reach 8.13 in one year’s time.
Technical Analysis of Halozyme Therapeutics Inc (HALO)
Compared to the last year’s volume of 2.03 million, its volume of 2.3 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 77.48%.
During the past 100 days, Halozyme Therapeutics Inc’s (HALO) raw stochastic average was set at 66.70%, which indicates a significant decrease from 70.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.38 in the past 14 days, which was higher than the 1.78 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $70.27, while its 200-day Moving Average is $62.32. Nevertheless, the first resistance level for the watch stands at $71.14 in the near term. At $72.26, the stock is likely to face the second major resistance level. The third major resistance level sits at $72.97. If the price goes on to break the first support level at $69.32, it is likely to go to the next support level at $68.60. Now, if the price goes above the second support level, the third support stands at $67.49.
Halozyme Therapeutics Inc (NASDAQ: HALO) Key Stats
There are 117,597K outstanding shares of the company, which has a market capitalization of 8.24 billion. As of now, sales total 1,015 M while income totals 444,090 K. Its latest quarter income was 354,260 K while its last quarter net income were 175,230 K.
